Ipsen has expanded its partnership with Exelixis to develop Cabometyx on the basis of a P-III (CABINET) study, funded by NCI, assessing Cabometyx vs PBO in advanced pancreatic neuroendocrine tumors (pNETs) & advanced extra-pancreatic neuroendocrine tumors (epNETs) patients (n=290; pNET: 93, epNET: 197) post prior therapy across the US
Study depicted mPFS of 11.4mos. vs 3mos. in the pNET arm at 16.7mos. median follow-up & 8.3mos. vs 3.2mos. in the epNET arm at 13.9mos. median follow-up
The decision expands on the current partnership looking for approval in the same indication outside of the US & Japan. Ipsen will make regulatory submissions to the EU regulatory authorities based on these results
Ref: Ipsen | Image: Ipsen
Related News:- Ipsen’s Iqirvo (Elafibranor) Gains the US FDA’s Accelerated Approval for Treating Primary Biliary Cholangitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
